The role of dopamine in the brain - Lessons learned from Parkinson's disease

Parkinson's disease causes a characteristic combination of motor symptoms due to progressive neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta. The core impairment of dopaminergic neurotransmission has motivated the use of functional magnetic resonance imaging (fMRI) in patients with Parkinson's disease to elucidate the role of dopamine in motor control and cognition in humans. Here we review the main insights from functional brain imaging in Parkinson's disease. Task-related fMRI revealed many disease-related alterations in brain activation patterns. However, the interpretation of these findings is complicated by the fact that task-dependent activity is influenced by complex interactions between the amount of dopaminergic neurodegeneration in the task-relevant nuclei, the state of medication, genetic factors and performance. Despite these ambiguities, fMRI studies in Parkinson's disease demonstrated a central role of dopamine in the generation of movement vigour (bradykinesia) and the control of excessive movements (dyskinesia), involving changes of both activity and connectivity of the putamen, premotor and motor regions, and right inferior frontal gyrus (rIFG). The fMRI studies addressing cognitive flexibility provided convergent evidence for a non-linear, U-shaped, relationship between dopamine levels and performance. The amount of neurodegeneration in the task-relevant dopaminergic nuclei and pharmacological dopamine replacement can therefore move performance either away or towards the task-specific optimum. Dopamine levels also strongly affect processing of reward and punishment for optimal learning. However, further studies are needed for a detailed understanding of the mechanisms underlying these effects.

[1]  Peter S. Jones,et al.  Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures , 2016, Human brain mapping.

[2]  M. Gluck,et al.  Dopaminergic Drugs Modulate Learning Rates and Perseveration in Parkinson's Patients in a Dynamic Foraging Task , 2009, The Journal of Neuroscience.

[3]  Marios Politis,et al.  Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. , 2013, Brain : a journal of neurology.

[4]  Ji Hyun Ko,et al.  Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study , 2012, Neurobiology of Disease.

[5]  B. Forstmann,et al.  Frontosubthalamic Circuits for Control of Action and Cognition , 2016, The Journal of Neuroscience.

[6]  K. Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[7]  T. Robbins,et al.  Chemical neuromodulation of frontal-executive functions in humans and other animals , 2000, Experimental Brain Research.

[8]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[9]  K. Jellinger Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.

[10]  Timothy E. J. Behrens,et al.  Learning the value of information in an uncertain world , 2007, Nature Neuroscience.

[11]  Antonio Cerasa,et al.  The motor inhibition system in Parkinson's disease with levodopa‐induced dyskinesias , 2015, Movement disorders : official journal of the Movement Disorder Society.

[12]  Adam R. Aron,et al.  Is executive control used to compensate for involuntary movements in levodopa‐induced dyskinesia? , 2012, Movement disorders : official journal of the Movement Disorder Society.

[13]  P. Dayan,et al.  Dopamine Increases a Value-Independent Gambling Propensity , 2016, Neuropsychopharmacology.

[14]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[15]  Hartwig R. Siebner,et al.  The motor system and its disorders , 2012, NeuroImage.

[16]  Antonio Cerasa,et al.  A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. , 2015, Brain : a journal of neurology.

[17]  S. Eickhoff,et al.  Functional neuroimaging of motor control in parkinson's disease: A meta‐analysis , 2014, Human brain mapping.

[18]  L. Timmermann,et al.  A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role? , 2015, Cortex.

[19]  M. Hallett,et al.  Dopamine agonists and risk: impulse control disorders in Parkinson's disease. , 2011, Brain : a journal of neurology.

[20]  W. Schultz Reward prediction error , 2017, Current Biology.

[21]  Thomas Foltynie,et al.  Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease. , 2018, Brain : a journal of neurology.

[22]  S. Haber The primate basal ganglia: parallel and integrative networks , 2003, Journal of Chemical Neuroanatomy.

[23]  R. Cilia,et al.  Impulse control disorders in Parkinson’s disease: seeking a roadmap toward a better understanding , 2011, Brain Structure and Function.

[24]  Roger A. Barker,et al.  Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis , 2012, Neurodegenerative Diseases.

[25]  A. Strafella,et al.  Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.

[26]  W Birkmayer,et al.  The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. , 2001, Wiener klinische Wochenschrift.

[27]  M. Pessiglione,et al.  A Selective Role for Dopamine in Learning to Maximize Reward But Not to Minimize Effort: Evidence from Patients with Parkinson's Disease , 2017, The Journal of Neuroscience.

[28]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[29]  Matthew F. S. Rushworth,et al.  Weighing up the benefits of work: Behavioral and neural analyses of effort-related decision making , 2006, Neural Networks.

[30]  C. Halldin,et al.  Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy , 2008, Neurology.

[31]  K. Ray Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[32]  D. Eckstein,et al.  Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition , 2008, Brain : a journal of neurology.

[33]  B. Forstmann,et al.  Neurocognitive mechanisms of action control: resisting the call of the Sirens. , 2011, Wiley interdisciplinary reviews. Cognitive science.

[34]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[35]  Yi Li,et al.  Dopamine Is Required for the Neural Representation and Control of Movement Vigor , 2015, Cell.

[36]  M. Husain,et al.  Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson’s disease , 2018, Brain : a journal of neurology.

[37]  P. Calabresi,et al.  Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors , 1997, The Journal of Neuroscience.

[38]  G C Cotzias,et al.  L-dopa in parkinson's syndrome. , 1969, The New England journal of medicine.

[39]  H. Braak,et al.  A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.

[40]  J. Massano,et al.  Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. , 2012, Cold Spring Harbor perspectives in medicine.

[41]  Alfonso Barrós-Loscertales,et al.  Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements , 2007, Brain Research.

[42]  M. Gluck,et al.  Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. , 2009, Brain : a journal of neurology.

[43]  Marianna Amboni,et al.  The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa , 2014, Brain : a journal of neurology.

[44]  Robert A. Hauser,et al.  Levodopa: Past, Present, and Future , 2008, European Neurology.

[45]  Michael C. Anderson,et al.  Selection and stopping in voluntary action: A meta-analysis and combined fMRI study , 2014, NeuroImage.

[46]  Antonio P. Strafella,et al.  Top-down Control of Dyskinesias in PD Using Brain Stimulation , 2014, Brain Stimulation.

[47]  Chris C. Tang,et al.  Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease , 2010, The Journal of Neuroscience.

[48]  Roshan Cools,et al.  Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective , 2014, Movement disorders : official journal of the Movement Disorder Society.

[49]  P. Smittenaar,et al.  Decomposing effects of dopaminergic medication in Parkinson’s disease on probabilistic action selection – learning or performance? , 2012, The European journal of neuroscience.

[50]  Ji Hyun Ko,et al.  Metabolic resting-state brain networks in health and disease , 2015, Proceedings of the National Academy of Sciences.

[51]  Scott T Grafton,et al.  The functional anatomy of parkinsonian bradykinesia , 2003, NeuroImage.

[52]  M. Husain,et al.  Dopamine enhances willingness to exert effort for reward in Parkinson's disease , 2015, Cortex.

[53]  Luca Passamonti,et al.  Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease , 2016, Neuropsychopharmacology.

[54]  U Sabatini,et al.  Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. , 1998, Brain : a journal of neurology.

[55]  Roger A. Barker,et al.  Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions , 2012, Cerebral cortex.

[56]  Caroline H. Williams-Gray,et al.  The Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease , 2016, Front. Psychiatry.

[57]  G. Berns Functional neuroimaging. , 1999, Life sciences.

[58]  John G Nutt,et al.  Pharmacokinetics and pharmacodynamics of levodopa , 2008, Movement disorders : official journal of the Movement Disorder Society.

[59]  D. Aarsland,et al.  A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[60]  H. Forssberg,et al.  Coordination of Manipulative Forces in Parkinson's Disease , 1997, Experimental Neurology.

[61]  Anne G E Collins,et al.  Opponent actor learning (OpAL): modeling interactive effects of striatal dopamine on reinforcement learning and choice incentive. , 2014, Psychological review.

[62]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[63]  Robert C. Wilson,et al.  An Approximately Bayesian Delta-Rule Model Explains the Dynamics of Belief Updating in a Changing Environment , 2010, The Journal of Neuroscience.

[64]  Jakob Kisbye Dreyer,et al.  How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum , 2016, Movement disorders : official journal of the Movement Disorder Society.

[65]  James B. Rowe,et al.  Multiple Modes of Impulsivity in Parkinson's Disease , 2014, PloS one.

[66]  M. Hallett,et al.  A physiological mechanism of bradykinesia. , 1980, Brain : a journal of neurology.

[67]  G. Steg,et al.  THE EFFECT OF L-3, 4-DIHYDROXYPHENYLALANINE AND DL-5-HYDROXYTRYPTOPHAN ON RIGIDITY AND TREMOR INDUCED BY RESERPINE, CHLORPROMAZINE AND PHENOXYBENZAMINE. , 1964, Life sciences.

[68]  Michael J Frank,et al.  Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update , 2017, The Lancet Neurology.

[69]  D J Brooks,et al.  Neuroimaging of dyskinesia. , 2000, Annals of neurology.

[70]  Jan Booij,et al.  Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[71]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[72]  R. Morris,et al.  Dopamine and Memory: Modulation of the Persistence of Memory for Novel Hippocampal NMDA Receptor-Dependent Paired Associates , 2010, The Journal of Neuroscience.

[73]  Viviana Versace,et al.  Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson’s disease , 2006, Clinical Neurophysiology.

[74]  M. Desmurget,et al.  A Common Optimization Principle for Motor Execution in Healthy Subjects and Parkinsonian Patients , 2013, The Journal of Neuroscience.

[75]  Fabrizio Esposito,et al.  Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. , 2013, Brain : a journal of neurology.

[76]  Edna Ty,et al.  Dyskinetic Parkinson’s disease patients demonstrate motor abnormalities off medication , 2011, Experimental Brain Research.

[77]  Roger A. Barker,et al.  Improving Response Inhibition in Parkinson’s Disease with Atomoxetine , 2015, Biological Psychiatry.

[78]  Jon E. Grant,et al.  Impulse Control Disorders: Updated Review of Clinical Characteristics and Pharmacological Management , 2011, Front. Psychiatry.

[79]  Roger A. Barker,et al.  Atomoxetine restores the response inhibition network in Parkinson’s disease , 2016, Brain : a journal of neurology.

[80]  C. Büchel,et al.  Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. , 2003, Brain : a journal of neurology.

[81]  D. Aarsland,et al.  A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[82]  J. Daunizeau,et al.  Computational Dissection of Dopamine Motor and Motivational Functions in Humans , 2016, The Journal of Neuroscience.

[83]  D. Lulé,et al.  Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study. , 2009, Parkinsonism & related disorders.

[84]  M. Hallett,et al.  Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors , 2010, Neuron.

[85]  C Caltagirone,et al.  rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease , 2005, Neurology.

[86]  Daniel Weintraub,et al.  Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[87]  V Kaasinen,et al.  Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.

[88]  A. Strafella,et al.  Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.

[89]  Roshan Cools,et al.  Greater striatal responses to medication in Parkinson׳s disease are associated with better task-switching but worse reward performance , 2014, Neuropsychologia.

[90]  Kristoffer Hougaard Madsen,et al.  Simultaneous representation of a spectrum of dynamically changing value estimates during decision making , 2017 .

[91]  Alexander Münchau,et al.  Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease. , 2013, Brain : a journal of neurology.

[92]  R. Cools Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease , 2006, Neuroscience & Biobehavioral Reviews.

[93]  Hartwig R. Siebner,et al.  Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans , 2015, Brain : a journal of neurology.

[94]  P. Goldman-Rakic,et al.  Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys , 1994, Psychopharmacology.

[95]  Sylvain Houle,et al.  [11C]‐(+)‐PHNO PET imaging of dopamine D2/3 receptors in Parkinson's disease with impulse control disorders , 2015, Movement disorders : official journal of the Movement Disorder Society.

[96]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[97]  T. Robbins,et al.  Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. , 2001, Cerebral cortex.

[98]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[99]  Xiaowei Zhuang,et al.  Incorporating spatial constraint in co-activation pattern analysis to explore the dynamics of resting-state networks: An application to Parkinson's disease , 2018, NeuroImage.

[100]  E. Montgomery Pharmacokinetics and pharmacodynamics of levodopa , 1992, Neurology.

[101]  Ulrik R Beierholm,et al.  Dopamine Modulates Reward-Related Vigor , 2013, Neuropsychopharmacology.

[102]  B. Averbeck,et al.  Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. , 2013, Behavioral neuroscience.

[103]  R. Barker,et al.  The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease , 2010, Neurobiology of Aging.

[104]  M. Cenci,et al.  Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia , 2006, Journal of neurochemistry.

[105]  Ruth Sander Impulse control disorders and levodopa-induced dyskinesias , 2017 .

[106]  Marjan Jahanshahi,et al.  Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson’s disease , 2011, Experimental Brain Research.

[107]  Roshan Cools,et al.  Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss , 2012, NeuroImage.

[108]  P. Strick,et al.  Imaging the premotor areas , 2001, Current Opinion in Neurobiology.

[109]  J. Krakauer,et al.  Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation , 2007, The Journal of Neuroscience.

[110]  F. Vingerhoets,et al.  Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? , 1997, Annals of neurology.

[111]  Rachel Tomer,et al.  Effects of asymmetric dopamine depletion on sensitivity to rewarding and aversive stimuli in Parkinson's disease , 2013, Neuropsychologia.

[112]  Hartwig R. Siebner,et al.  The acute brain response to levodopa heralds dyskinesias in Parkinson disease , 2014, Annals of neurology.

[113]  R. Barker,et al.  Parkinson's disease and healthy aging: Independent and interacting effects on action selection , 2010, Human brain mapping.

[114]  Kristoffer Hougaard Madsen,et al.  Motivational Tuning of Fronto-Subthalamic Connectivity Facilitates Control of Action Impulses , 2014, The Journal of Neuroscience.

[115]  David J. Brooks,et al.  Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study , 2014, Brain : a journal of neurology.

[116]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[117]  C. Kennard,et al.  Functional role of the supplementary and pre-supplementary motor areas , 2008, Nature Reviews Neuroscience.

[118]  M. Pessiglione,et al.  Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes , 2009, Proceedings of the National Academy of Sciences.

[119]  S. Houle,et al.  Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.

[120]  J. Krakauer,et al.  The basal ganglia: from motor commands to the control of vigor , 2016, Current Opinion in Neurobiology.

[121]  A Verniory,et al.  Serum renin levels and postnephrectomy blood pressure. , 1969, The New England journal of medicine.

[122]  Oury Monchi,et al.  The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward , 2017, Movement disorders : official journal of the Movement Disorder Society.

[123]  M. A. MacIver,et al.  Neuroscience Needs Behavior: Correcting a Reductionist Bias , 2017, Neuron.

[124]  Erin Kendall Braun,et al.  Mind matters: Placebo enhances reward learning in Parkinson’s disease , 2014, Nature Neuroscience.

[125]  Kalen J. Petersen,et al.  Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors , 2017, Movement disorders : official journal of the Movement Disorder Society.

[126]  A. Lang,et al.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.

[127]  Antonio Cerasa,et al.  Increased prefrontal volume in PD with levodopa‐induced dyskinesias: A voxel‐based morphometry study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[128]  V. Menon,et al.  Compensatory neural mechanisms in cognitively unimpaired Parkinson disease , 2016, Annals of neurology.

[129]  Stephanie L. Alberico,et al.  The Vulnerable Ventral Tegmental Area in Parkinson's Disease. , 2015, Basal ganglia.

[130]  D. Vaillancourt,et al.  Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease , 2010, Human brain mapping.

[131]  D. Eidelberg Metabolic brain networks in neurodegenerative disorders: a functional imaging approach , 2009, Trends in Neurosciences.

[132]  Valerie Voon,et al.  Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[133]  R. Bogacz,et al.  Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making , 2012, Brain : a journal of neurology.

[134]  T. Robbins,et al.  L-DOPA Disrupts Activity in the Nucleus Accumbens during Reversal Learning in Parkinson's Disease , 2007, Neuropsychopharmacology.

[135]  Dagmar Verbaan,et al.  Cognitive impairment in Parkinson's , 2007 .

[136]  M Schulzer,et al.  PET demonstrates reduced dopamine transporter expression in PD with dyskinesias , 2009, Neurology.

[137]  M. Hallett,et al.  Pathophysiology of bradykinesia in Parkinson's disease. , 2001, Brain : a journal of neurology.

[138]  R. Bogacz,et al.  Effects of dopamine on reinforcement learning and consolidation in Parkinson’s disease , 2017, eLife.

[139]  Antonio Cerasa,et al.  Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease , 2015, Front. Neurol..

[140]  R. Cools,et al.  Reward learning deficits in Parkinson’s disease depend on depression , 2016, bioRxiv.

[141]  George I. Christopoulos,et al.  Neural Correlates of Value, Risk, and Risk Aversion Contributing to Decision Making under Risk , 2009, The Journal of Neuroscience.

[142]  W Birkmayer,et al.  The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. , 1998, Parkinsonism & related disorders.

[143]  John C Rothwell,et al.  Can levodopa-induced dyskinesias go beyond the motor circuit? , 2015, Brain : a journal of neurology.

[144]  Karl J. Friston,et al.  The Trouble with Cognitive Subtraction , 1996, NeuroImage.

[145]  Bradley L. Schlaggar,et al.  The Fallacy of Univariate Solutions to Complex Systems Problems , 2016, Front. Neurosci..

[146]  Hartwig R. Siebner,et al.  Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[147]  Raymond J. Dolan,et al.  Value encoding in the globus pallidus: fMRI reveals an interaction effect between reward and dopamine drive , 2017, NeuroImage.

[148]  Timothy Edward John Behrens,et al.  Changes in connectivity profiles define functionally distinct regions in human medial frontal cortex. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[149]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[150]  Sylvain Houle,et al.  Abnormal intrinsic brain functional network dynamics in Parkinson’s disease , 2017, Brain : a journal of neurology.

[151]  M. Frank,et al.  Computational psychiatry as a bridge from neuroscience to clinical applications , 2016, Nature Neuroscience.

[152]  Elias Aboujaoude,et al.  Impulse Control Disorders: Impulse Control Disorders , 2010 .

[153]  Michael J. Frank,et al.  By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism , 2004, Science.

[154]  Brian A. Nosek,et al.  Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.

[155]  Chonho Lee,et al.  Excessive Sensitivity to Uncertain Visual Input in L-DOPA-Induced Dyskinesias in Parkinson’s Disease: Further Implications for Cerebellar Involvement , 2013, Front. Neurol..

[156]  Penny A. MacDonald,et al.  The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. , 2011, Brain : a journal of neurology.

[157]  David Eidelberg,et al.  Parkinson's disease‐related network topographies characterized with resting state functional MRI , 2017, Human brain mapping.

[158]  P. Dayan,et al.  Tonic dopamine: opportunity costs and the control of response vigor , 2007, Psychopharmacology.

[159]  W. Schultz Neuronal Reward and Decision Signals: From Theories to Data. , 2015, Physiological reviews.

[160]  P. Strick,et al.  Frontal lobe inputs to primate motor cortex: evidence for four somatotopically organized ‘premotor’ areas , 1979, Brain Research.

[161]  Roger A. Barker,et al.  Genetic Neuroimaging Studies of Basal Ganglia Disorders , 2016 .

[162]  P. Dayan,et al.  Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease. , 2012 .

[163]  Marios Politis,et al.  Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.

[164]  J. H. Krystal,et al.  208. Increased striatal dopamine release in drug free schizophrenic subjects , 1996, Biological Psychiatry.

[165]  Antonio Cerasa,et al.  Prefrontal alterations in Parkinson's disease with levodopa‐induced dyskinesia during fMRI motor task , 2012, Movement disorders : official journal of the Movement Disorder Society.

[166]  G. Deuschl,et al.  Force overflow and levodopa-induced dyskinesias in Parkinson's disease. , 2002, Brain : a journal of neurology.

[167]  A. Strafella,et al.  Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling , 2010, Neurobiology of Disease.

[168]  Thomas Foltynie,et al.  Parkinson’s disease dementia: a neural networks perspective , 2015, Brain : a journal of neurology.

[169]  A M Owen,et al.  Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. , 2013, Cerebral cortex.